China Oncology Focus: funding combinations
Lee’s spinout China Oncology Focus is banking on in-house combinations
China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking venture financing to help it meet its goal of submitting NDAs in China for four oncology programs by YE21.
China Oncology Focus Ltd. (COF) spun out of Lee’s Pharmaceutical Holdings Ltd. last August with China rights to five novel oncology programs